Cytogenetic Studies in Acute Leukemia and Multiple Myeloma

StatusActive, Not Recruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 394 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. 4 versions Re-verified since Jan 22, 2019, no change to tracked fieldsv391-v394
  2. Site details revised at 1 of 137 sitesv390
  3. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 137 of 137 sites
    v389
  4. Re-verified, no change to tracked fieldsv388
  5. Phase: Not applicable to Not specifiedv387 Show 10 more changesShow less
    • Lead sponsor: Cancer and Leukemia Group B to Alliance for Clinical Trials in Oncology
    • Trial status: Withdrawn to Recruiting
    • Primary completion date: Jul 2005 to Jan 2100
    • Enrollment target: 0 to 9000
    • Interventions: chromosomal translocation analysis (Genetic), cytogenetic analysis (Genetic) to cytogenetic analysis (Genetic)
    • Eligibility criteria shortened, about 37 words
    • Study description shortened, about 172 words
    • Site details revised at 137 of 137 sites
    • Study title shortened, about 8 words
    • Study arms: 0 to 1
Show 42 earlier versionsHide 42 earlier versions
  1. Trial status: Recruiting to Withdrawn
    • Enrollment target: estimated 6400 to confirmed 0
    • Study sites: 140 to 137
    v386
  2. Study sites: 139 to 140v385
  3. Study sites: 142 to 139v384
  4. Study sites: 143 to 142v383
  5. Site contacts updated at 1 of 143 sitesv382
  6. Study sites: 142 to 143v381
  7. Study sites revised (142)v380
  8. Study sites: 141 to 142v379
  9. Study sites revised (141)v378
  10. Study sites: 142 to 141v377
  11. Study sites: 143 to 142v376
  12. Study sites: 141 to 143v375
  13. Study sites: 143 to 141v374
  14. Study sites: 144 to 143v373
  15. Study sites: 143 to 144v372
  16. Study sites: 142 to 143v371
  17. Study sites: 143 to 142v370
  18. Study sites: 141 to 143v369
  19. Study sites: 142 to 141v368
  20. Study sites: 141 to 142v367
  21. Study sites: 142 to 141v366
  22. Study sites: 141 to 142v365
  23. Study sites: 142 to 141v364
  24. Study sites: 143 to 142v363
  25. Study sites: 142 to 143v362
  26. Study sites: 143 to 142v361
  27. Study sites: 142 to 143v360
  28. Study sites: 143 to 142v359
  29. Study sites: 142 to 143v358
  30. Study sites: 144 to 142v357
  31. Study sites: 143 to 144v356
  32. Study sites revised (143)v355
  33. Study sites: 145 to 143v354
  34. Study sites: 147 to 145v353
  35. Study sites: 146 to 147v352
  36. Study sites: 147 to 146v351
  37. Study sites: 151 to 147v350
  38. Study sites: 150 to 151v349
  39. Study sites: 151 to 150v348
  40. Study sites: 149 to 151v347
  41. Study sites: 150 to 149v346
  42. Study sites: 151 to 150v345
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Chromosomal analysis or the study of genetic differences in patients previously untreated with AML, ALL, MDS or MM may be helpful in the diagnosis and classification of disease. It may also improve the ability to predict the course of disease and the selection of therapy. Institutions must have either an Alliance-approved cytogeneticist or an agreement from an Alliance-approved main member cytogenetics laboratory to enroll a patient on CALGB 8461. The Alliance Approved Institutional Cytogeneticists list is posted on the Alliance for Clinical Trials in Oncology website.
Trial Details
NCT Number NCT00048958
Lead Sponsor Alliance for Clinical Trials in Oncology
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Acute Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Multiple Myeloma
Related terms Multiple Myeloma, Myelodysplastic Syndromes, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Enrollment 9,000 participants
Start Date
Primary Completion (estimated)
Updated on ClinicalTrials.gov